How much did Geneuro achieve in EBIT for the current year?
In the current year, Geneuro has achieved an EBIT of -10.91 M EUR.
Geneuro EBIT 2024
Geneuro EBIT
-10.91 M EUR
Ticker
GNRO.PA
ISIN
CH0308403085
WKN
A2AHDP
In 2024, Geneuro's EBIT was -10.91 M EUR, a -23.98% increase from the -14.36 M EUR EBIT recorded in the previous year.
The Geneuro EBIT history
| YEAR | EBIT (undefined EUR) |
|---|---|
| 2025e | -9.76 |
| 2024e | -10.91 |
| 2023 | -14.36 |
| 2022 | -11.23 |
| 2021 | -6.37 |
| 2020 | -7.46 |
| 2019 | -8.99 |
| 2018 | -8.09 |
| 2017 | -5.74 |
| 2016 | -14.04 |
| 2015 | -4.32 |
| 2014 | 2.2 |
| 2013 | -3.35 |
Geneuro Revenue, EBIT, Net Income CH0308403085 · A2AHDP
3 years
5 years
10 years
25 Years
Max
Revenue
EBIT
Net Income
Details
Revenue, EBIT and Profit
ⓘUnderstanding Revenue, EBIT, and Income
Gain insights into Geneuro, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Geneuro from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Geneuro’s net earnings, an ultimate measure of its financial health and profitability.
Yearly Analysis and Comparisons
Observe the yearly bars to understand the annual performance and growth of Geneuro. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.
Utilizing Expectations for Investment
The expected values for the forthcoming years offer investors a glimpse into Geneuro’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.
Investment Insights
Leveraging the comparison between Revenue and EBIT helps in assessing Geneuro’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Geneuro’s growth potential.
Geneuro Revenue, EBIT and net profit per share
| Date | Geneuro Revenue | Geneuro EBIT | Geneuro Net Income |
|---|---|---|---|
| 2025e | 11.03 M undefined | -9.76 M undefined | -7.81 M undefined |
| 2024e | 0 undefined | -10.91 M undefined | -12.33 M undefined |
| 2023 | 0 undefined | -14.36 M undefined | -14.76 M undefined |
| 2022 | 0 undefined | -11.23 M undefined | -12.2 M undefined |
| 2021 | 0 undefined | -6.37 M undefined | -6.82 M undefined |
| 2020 | 0 undefined | -7.46 M undefined | -8.96 M undefined |
| 2019 | 0 undefined | -8.99 M undefined | -9.46 M undefined |
| 2018 | 7.46 M undefined | -8.09 M undefined | -8.33 M undefined |
| 2017 | 14.95 M undefined | -5.74 M undefined | -5.84 M undefined |
| 2016 | 5.92 M undefined | -14.04 M undefined | -14.1 M undefined |
| 2015 | 2.54 M undefined | -4.32 M undefined | -4.49 M undefined |
| 2014 | 7.31 M undefined | 2.2 M undefined | 1.78 M undefined |
| 2013 | 20,000 undefined | -3.35 M undefined | -3.5 M undefined |
| Revenue | EBIT | Net Income | |
|---|---|---|---|
| 2013 | 20,000 EUR | -3.35 M EUR | -3.5 M EUR |
| 2014 | 7.31 M EUR | 2.2 M EUR | 1.78 M EUR |
| 2015 | 2.54 M EUR | -4.32 M EUR | -4.49 M EUR |
| 2016 | 5.92 M EUR | -14.04 M EUR | -14.1 M EUR |
| 2017 | 14.95 M EUR | -5.74 M EUR | -5.84 M EUR |
| 2018 | 7.46 M EUR | -8.09 M EUR | -8.33 M EUR |
| 2019 | 0 EUR | -8.99 M EUR | -9.46 M EUR |
| 2020 | 0 EUR | -7.46 M EUR | -8.96 M EUR |
| 2021 | 0 EUR | -6.37 M EUR | -6.82 M EUR |
| 2022 | 0 EUR | -11.23 M EUR | -12.2 M EUR |
| 2023 | 0 EUR | -14.36 M EUR | -14.76 M EUR |
| 2024e | 0 EUR | -10.91 M EUR | -12.33 M EUR |
| 2025e | 11.03 M EUR | -9.76 M EUR | -7.81 M EUR |
Geneuro stock margins CH0308403085 · A2AHDP
The Geneuro margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Geneuro. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Geneuro.
3 years
5 years
10 years
25 Years
Max
Gross margin
EBIT margin
Profit margin
Details
Margin
ⓘUnderstanding Gross Margin
The gross margin, expressed as a percentage, delineates the gross profit made from the Geneuro's sales revenue. A higher gross margin percentage indicates that the Geneuro retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.
EBIT Margin Analysis
EBIT margin represents the Geneuro's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.
Revenue Margin Insights
The revenue margin demonstrates the Geneuro's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Geneuro's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.
Interpreting Expectations
The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Geneuro. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.
Comparative Analysis
Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Geneuro's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.
Geneuro Margin History
| Geneuro Gross margin | Geneuro Profit margin | Geneuro EBIT margin | Geneuro Profit margin |
|---|---|---|---|
| 2025e | 0 % | -88.56 % | -70.88 % |
| 2024e | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2019 | 0 % | 0 % | 0 % |
| 2018 | 0 % | -108.38 % | -111.59 % |
| 2017 | 0 % | -38.4 % | -39.05 % |
| 2016 | 0 % | -237.21 % | -238.33 % |
| 2015 | 0 % | -170.23 % | -176.71 % |
| 2014 | 0 % | 30.13 % | 24.32 % |
| 2013 | 0 % | -16,750 % | -17,500 % |
| Gross margin | EBIT margin | Profit margin | |
|---|---|---|---|
| 2013 | 0 % | -16,750 % | -17,500 % |
| 2014 | 0 % | 30.13 % | 24.32 % |
| 2015 | 0 % | -170.23 % | -176.71 % |
| 2016 | 0 % | -237.21 % | -238.33 % |
| 2017 | 0 % | -38.4 % | -39.05 % |
| 2018 | 0 % | -108.38 % | -111.59 % |
| 2019 | 0 % | 0 % | 0 % |
| 2020 | 0 % | 0 % | 0 % |
| 2021 | 0 % | 0 % | 0 % |
| 2022 | 0 % | 0 % | 0 % |
| 2023 | 0 % | 0 % | 0 % |
| 2024e | 0 % | 0 % | 0 % |
| 2025e | 0 % | -88.56 % | -70.88 % |
Geneuro Aktienanalyse
What does Geneuro do?
Geneuro SA is a biopharmaceutical company based in Plan-les-Ouates, Geneva, Switzerland. It was founded in 2007 and focuses on the development of innovative therapies for autoimmune diseases and other neurological disorders. Geneuro was founded based on research by Prof. Jean-Michel Goust, a renowned pain therapist and neuroimmunologist. In collaboration with distinguished scientists and experts in the field of neuroimmunology and neurovirology, he developed a new concept for combating autoimmune diseases of the nervous system, such as multiple sclerosis. Geneuro's business model is centered around developing novel therapeutics for chronic neurological disorders, particularly through immunomodulation. The drugs aim to help regulate the body's immune system to suppress inflammatory reactions in the brain, thereby preventing or at least reducing the adverse effects of autoimmune diseases. The company divides its activities into two main areas: research and development of novel therapeutics, and marketing of products. In the research and development field, Geneuro works closely with various partners such as universities, research institutes, and other companies. The aim is to translate the latest scientific knowledge in the fields of neuroimmunology and neurovirology into clinical practice in order to provide patients with better treatment options. Geneuro has focused on a specific class of drugs known as "anti-HERV," which stands for "human endogenous retroviruses." These retroviral particles make up approximately five percent of the human genome and are currently an active research area in neuroimmunology. Geneuro has developed a method to produce specific antibodies against these retroviruses and utilizes these antibodies as therapeutics in the fight against autoimmune diseases. The leading product of Geneuro in this area is GNbAC1, a novel monoclonal antibody preparation against the HERV virus, which was developed in collaboration with Merck Serono. GNbAC1 is currently in the clinical testing phase (Phase III) and has already shown promising results. It demonstrates significant efficacy in the treatment of multiple sclerosis and is also being tested for the treatment of other neuroimmunological diseases such as neuromyelitis optica and amyotrophic lateral sclerosis. In addition to GNbAC1, Geneuro has other products in the development phase. These include GNbAC2, a product specifically developed for the Japanese market in collaboration with Toyama Chemical Co., Ltd., and GNbAC-K9, a product for dogs designed to treat degenerative central nervous system disorders. Geneuro's second business area involves the marketing of its products. The company collaborates with both large pharmaceutical companies and smaller biotech companies worldwide to broaden the reach of their products. In recent years, Geneuro has established itself as a significant player in the field of neurological disorders. The company has developed promising therapies for autoimmune diseases that regulate the body's immune system in an innovative way. Geneuro's antibody preparations aim to target a specific class of proteins to contain inflammation in the brain and achieve broader efficacy in the treatment of neurological diseases such as MS. The company has set ambitious goals to improve its products and enhance its innovation capabilities, and will continue to drive significant developments in the future. Geneuro ist eines der beliebtesten Unternehmen auf Eulerpool.com.EBIT Details
Analyzing Geneuro's EBIT
Geneuro's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.
Year-to-Year Comparison
A yearly comparison of Geneuro's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.
Impact on Investments
Geneuro's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.
Interpreting EBIT Fluctuations
Fluctuations in Geneuro’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.
Frequently Asked Questions about Geneuro stock
What is EBIT?
EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company Geneuro.
How has the EBIT of Geneuro developed in recent years?
The EBIT of Geneuro has increased by -23.983% decreased compared to the previous year.
What does EBIT mean for investors?
EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.
Why is EBIT an important indicator for investors?
Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.
Why do EBIT values fluctuate?
EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.
What role does tax burden play in EBIT?
Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.
How is EBIT presented in the balance sheet of the company Geneuro?
The EBIT of Geneuro is listed in the income statement.
Can EBIT be used as a single indicator for evaluating a company?
EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.
Why is EBIT not equal to net profit?
The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.
How much dividend does Geneuro pay?
Over the past 12 months, Geneuro paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geneuro is expected to pay a dividend of 0 EUR.
What is the dividend yield of Geneuro?
The current dividend yield of Geneuro is .
When does Geneuro pay dividends?
Geneuro pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Geneuro?
Geneuro paid dividends every year for the past 0 years.
What is the dividend of Geneuro?
For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.
In which sector is Geneuro located?
Geneuro is assigned to the 'Health' sector.
Wann musste ich die Aktien von Geneuro kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Geneuro from 8/26/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 8/26/2024.
When did Geneuro pay the last dividend?
The last dividend was paid out on 8/26/2024.
What was the dividend of Geneuro in the year 2023?
In the year 2023, Geneuro distributed 0 EUR as dividends.
In which currency does Geneuro pay out the dividend?
The dividends of Geneuro are distributed in EUR.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Geneuro
Our stock analysis for Geneuro Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geneuro Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
